Here are the S-1 registration statements from Mangoceuticals, Inc. (MGRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow MGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRX filings page.
Mangoceuticals, Inc. is registering 2,640,178 shares of common stock for resale by existing investors. The shares consist of 1,930,502 shares issuable upon exercise of warrants with a $1.4245 per share exercise price and 709,676 already issued shares that were sold at $1.55 per share to accredited investors.
The company is not selling any shares in this offering and will not receive proceeds from resale by the selling stockholders; it will receive cash only if the warrants are exercised, which it plans to use for general working capital. Mangoceuticals operates the MangoRX telehealth platform, offering compounded men’s wellness products and an FDA‑approved oral testosterone therapy, and relies on related-party pharmacy Epiq Scripts for compounding and fulfillment. Its common stock trades on Nasdaq under the symbol MGRX, with a last reported price of $0.537 per share on January 22, 2026.
Mangoceuticals, Inc. has filed a Form S-1 registering up to 2,640,178 shares of common stock for resale by existing stockholders. The shares consist of 1,930,502 shares issuable upon exercise of common stock purchase warrants at an exercise price of $1.4245 per share and 709,676 already issued shares that were sold to accredited investors at $1.55 per share. The company is not selling any shares itself in this offering and will not receive proceeds from stockholder resales, but would receive cash if holders exercise the warrants, which it plans to use for general working capital. The selling stockholders may sell their shares over time in various types of public or private transactions. Mangoceuticals’ common stock trades on Nasdaq under the symbol “MGRX”, and the last reported price on January 12, 2026 was $0.785 per share.